>
>
Toronto, Ontario–(Newsfile Corp. – August 10, 2022) – Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQX: KHRNF) (FSE: A2JMZC) (“Khiron” or the “Company”), a global leader
Continued Global Growth of Khiron’s Proven ZereniaTM Clinic ModelFocused on Patients, Physician Education and Innovation New clinic is in the district of Ipanema in Rio
Acquisition provides Khiron with an EU-GMP European manufacturing and distribution hub for medical cannabis and other pharmaceutical products The acquisition of Pharmadrug Production GmbH provides
TORONTO, July 18, 2022 /PRNewswire/ – Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a global leader in medical
Khiron’s Medical Clinics and Distribution Growth Throughout Europe Follows Success in Latin American Marketplace Since establishing a Spanish subsidiary in 2019, Khiron’s scientific and medical
Khiron Serves Record Number of Patients With Khiron Products Globally in Its Medical Treatment Clinics TORONTO, June 28, 2022 /PRNewswire/ – Khiron Life Sciences Corp.
khiron announces results of 2022 annual general and special meeting khiron announces results of 2022 annual general and special meeting canada newswire toronto june 23
khiron announces results of 2022 annual general and special meeting khiron announces results of 2022 annual general and special meeting pr newswire toronto june 23
TORONTO, June 23, 2022 /PRNewswire/ – Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a global leader in medical
khiron life sciences announces closing of $4 6 million overnight brokered offering including full exercise of over allotment option khiron life sciences announces closing of
